HC Wainwright Lifts Earnings Estimates for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – Equities researchers at HC Wainwright upped their FY2026 EPS estimates for Cabaletta Bio in a research note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($1.26) per share for the year, up from their prior estimate of ($1.35). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.27) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at ($0.53) EPS.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Several other brokerages have also issued reports on CABA. William Blair upgraded Cabaletta Bio to a “strong-buy” rating in a report on Wednesday, September 23rd. Wells Fargo & Company dropped their price objective on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. TD Cowen raised shares of Cabaletta Bio to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen raised shares of Cabaletta Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cabaletta Bio currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Cabaletta Bio Stock Up 15.4%

Shares of CABA stock opened at $1.50 on Tuesday. Cabaletta Bio has a fifty-two week low of $1.18 and a fifty-two week high of $4.23. The stock’s 50-day moving average is $2.09 and its two-hundred day moving average is $2.82.

Hedge Funds Weigh In On Cabaletta Bio

Several hedge funds have recently bought and sold shares of the business. StoneX Group Inc. acquired a new stake in shares of Cabaletta Bio in the third quarter worth about $26,000. Simplify Asset Management Inc. bought a new stake in shares of Cabaletta Bio during the 3rd quarter worth about $1,068,000. Nisa Investment Advisors LLC boosted its stake in shares of Cabaletta Bio by 3,976.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 33,061 shares of the company’s stock worth $63,000 after acquiring an additional 32,250 shares in the last quarter. Opaleye Management Inc. increased its holdings in shares of Cabaletta Bio by 180.0% during the 2nd quarter. Opaleye Management Inc. now owns 3,863,800 shares of the company’s stock valued at $12,016,000 after acquiring an additional 2,483,800 shares during the last quarter. Finally, WINTON GROUP Ltd increased its holdings in shares of Cabaletta Bio by 76.5% during the 2nd quarter. WINTON GROUP Ltd now owns 27,000 shares of the company’s stock valued at $84,000 after acquiring an additional 11,700 shares during the last quarter.

More Cabaletta Bio News

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026–2029, reflecting smaller expected losses, and reiterated its Buy rating with a $16 price target. For example, its FY2027 loss estimate improved to $1.02 per share from $1.29. Cabaletta Bio analyst coverage
• Positive Sentiment: New rese-cel Phase 1/2 results were encouraging: all six dermatomyositis patients maintained moderate-to-major responses without immunomodulators through one year, with most also off steroids. This may strengthen the case for the therapy, though the data are early-stage. Rese-cel Phase 1/2 data
• Neutral Sentiment: Citigroup cut its price target to $8 but maintained a Buy rating, leaving a positive recommendation while signaling a more cautious valuation view. Citigroup price-target update
• Negative Sentiment: A separate analyst reduced its FY2030 EPS estimate, a counterpoint to HC Wainwright’s improved forecasts. FY2030 EPS estimate change

Cabaletta Bio Company Profile

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.